LIVN News and Press, LivaNova PLC

2024-07-18 11:34:12 ET More on Health Care Select Sector SPDR® Fund ETF: XLV: A Strong Way To Benefit From An Aging And Unhealthy Population XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks BofA...

2024-07-12 13:02:50 ET More on Vanguard Growth ETF: VUG: Strong Focus On Tech Raises Concerns VUG: Jump Into The Bull Run As More Upside Is Ahead VUG: Way Too Risky Here BofA clients were net buyers of U.S. equities for the first week in six What's ne...

2024-07-03 13:34:14 ET Mizhuo picks Axsome Therapeutics ( AXSM ), Wave Life Sciences ( WVE ), Arcutis Biotherapeutics ( ARQT ), LivaNova ( LIVN ) and Humana ( HUM ) as July’s top picks.... Read the full article on Seeking Alpha For further details see:...

2024-06-23 00:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. ...

2024-06-06 22:23:41 ET Summary Greenlight Capital's 13F portfolio value increased from $2.05B to $2.18B in Q1 2024. New stakes include Penn Entertainment, HP Inc., Roivant Sciences, and Liberty Global. Stake disposals include Gulfport Energy, Herc Holdings, First Horizon Corp,...

2024-06-06 11:37:56 ET More on LivaNova PLC LivaNova: Focus Is Paying Off LivaNova PLC (LIVN) Q1 2024 Earnings Call Transcript LivaNova PLC 2024 Q1 - Results - Earnings Call Presentation LivaNova beats top-line and bottom-line estimates; raises FY24 outlook ...

2024-06-06 11:00:14 ET Rick Wise from Stifel Nicolaus issued a price target of $70.00 for LIVN on 2024-06-06 09:52:00. The adjusted price target was set to $70.00. At the time of the announcement, LIVN was trading at $53.16. The overall price target consensus is at $69.5...

Primary endpoint did not achieve statistical significance in unipolar patient cohort Statistically significant and clinically meaningful benefits seen in select secondary endpoints; no safety concerns identified LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology co...

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Goldman Sachs Healthcare Conference in Miami, Florida. The presentation will take place at 1:20 p.m. Eastern Time on Monda...